

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/516,381
	Filing Date	November 30, 2004
	First Named Inventor	Guenther Eissner
	Group Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	014442-000022

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group ( <i>Appeal Notice, Brief, Reply Brief</i> ) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of 10 Cited References; and Acknowledgment Postcard.
Remarks		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual Name	MICHAEL G. JOHNSTON MOORE & VAN ALLEN PLLC
Signature	
Date	1-6-05

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Laura McCullen
Signature	
Date	1-7-05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Guenther Eissner

Group Art Unit:

Serial Number: 10/516,381

Examiner:

Filed: November 30, 2004

For: METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS  
DURING CHEMOTHERAPY

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97**

It is respectfully requested that the document(s) listed on the attached Form PTO/SB/08A be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. Full text copies of the relevant documents are enclosed.

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. 37 CFR § 1.97(e)(1).

Respectfully submitted,


By:

  
Michael G. Johnston  
Registration No. 38,194  
Attorney for Applicant  
Moore & Van Allen, PLLC  
430 Davis Dr., Suite 500  
Morrisville, NC 27560-6832  
Phone: 919-286-8000  
Facsimile: 919-286-8199


1-6-05  
Date

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on January 7, 2005, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

  
Laura McCullen

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/516,381		
		Filing Date	November 30, 2004		
		First Named Inventor	Guenther Eissner		
		Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	014442-000022

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AB/	B	BAIREY OSNAT ET AL., "Clinical Severe Hepatic Venooclusive Disease During Induction Treatment of Acute Monoblastic Leukemia Managed With Defibrotide", American Journal of Hematology, April 2002, Pages 281-284, vol. 69, no. 4, Wiley-Liss, Inc., US.	
	C	RICHARDSON P G ET AL., "Multi-Institutional Phase II, Randomized Does Finding Study of Defibrotide (DF) in Patients (pts) with Severe Veno-Occulsive Disease (VOD) and Multi-System Organ Failure (MOF) Post Stem Cell Transplantation (SCT): Promising Response Rate Without Significant Toxicity in a High Risk Population", BLOOD, November 16, 2001, Page 853a, Vol. 98, No. 11, part 1, 43 <sup>rd</sup> Annual Meeting of the American Society of Hematology, Part 1, Orlando, Florida, US.	
	D	MIRANDA N ET AL., "Treatment of Hepatic Veno-occlusive Disease (VOD) with Defibrotide: Results in 5 Stem Cell Transplant Recipients", BLOOD, November 15, 1999, Page 359b, Vol 94, No. 10, Suppl. 1 Part 2, Forty-First Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, US.	
	E	SHAW BE ET AL., "The Use of Defibrotide in the Management of Vascular Endothelial Complications (VOD/HUS/TTP) of Stem Cell Transplantation", BLOOD, November 15, 1999, Page 608a, Vol. 94, No. 10, Suppl. 1 part 1, Forty-First Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, US.	
	F	SAYER H G ET AL., "Hepatic Veno-occlusive Disease (VOD) With Complete Occlusion of Liver Venules After Tandem Autologous Stem Cell Transplantation: Successful Treatment With High-Dose Methylprednisolone and Defibrotide", Journal of Cancer Research and Clinical Oncology, March 2002, Pages 148-152, Vol. 128, No. 3, Springer-Verlag.	
	G	MAISANO ROBERTO ET AL., "Defibrotide in the Prevention of Venous Irritation By Vinorelbine Administration", Anticancer Research, 1997, Pages 2775 - 2777, Vol. 17, No. 4A,	
	H	RICHARDSON PAUL G ET AL., "Treatment of Severe Veno-occlusive Disease With Defibrotide: Compassionate Use Results In Response Without Significant Toxicity In A High-Risk Population, BLOOD, August 1, 1998, Pages 737-744, Vol. 92, No. 3,	
	I	CHOPRA R ET AL., "Defibrotide For The Treatment of Hepatic Veno-occlusive Disease: Results of the European Compassionate-Use Study", BRITISH JOURNAL OF HAEMATOLOGY, December 4, 2000, Pages 1122-1129, Vol. 111, No. 4, Blackwell Science Ltd.	
	J	SCHROEDER HENNING, "Defibrotide Protects Endothelial Cells, But Not L929 Tumour Cells, From Tumour Necrosis Factor-Alpha-Medicated Cytotoxicity", JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, Vol. 47, No. 3, Pages 250- 252, J. Pharm. Pharmacol.	

Examiner Signature	/Amy Bowman/	Date Considered	05/19/2008
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.